|
WO2021079984A1
|
|
Novel substituted condensed ring compound
|
|
WO2021075545A1
|
|
Humanized antibody and method for using the same
|
|
WO2021060453A1
|
|
Crosslinked optically active secondary amine derivative
|
|
WO2021039961A1
|
|
Ring-fused pyrazole derivative
|
|
WO2021039968A1
|
|
2-aminoquinazolinone derivative
|
|
WO2021039616A1
|
|
Combination therapy and biomarker indicating efficacy thereof
|
|
WO2020251015A1
|
|
2-ALKYLCARBONYL[2,3-b]FURAN-4,9-DIONE PRODUCTION METHOD AND PRODUCTION INTERMEDIATE THEREFOR
|
|
WO2020213714A1
|
|
Method for producing cis-(-)-fluocino piperidol
|
|
WO2020204172A1
|
|
Water soluble adjuvant
|
|
WO2020204173A1
|
|
Water soluble adjuvant and composition containing same
|
|
TW202100169A
|
|
Method for evaluating quality of transplant neural retina, and transplant neural retina sheet
|
|
TW202100157A
|
|
Aqueous suspension pharmaceutical preparation with controlled particle size
|
|
TW202045528A
|
|
Method for selecting subject likely benefiting from pharmaceutical composition for treating or preventing cancer
|
|
WO2020166592A1
|
|
Hemiasterlin derivative and antibody-drug conjugate thereof
|
|
WO2020166613A1
|
|
Agent for eliminating pluripotent stem cells
|
|
WO2020166600A1
|
|
Hemiasterlin derivative having cysteine residue
|
|
US2020172543A1
|
|
Condensed lactam derivative
|
|
US2020157114A1
|
|
Optically active azabicyclo ring derivative
|
|
TW202038941A
|
|
Alkyl-substituted compound
|
|
WO2020138370A1
|
|
Cancer treatment pharmaceutical composition containing cdk inhibitor
|
